

Striking the Right Balance: The Role of n-3/n-6 Fatty Acid Ratio in Health and Strategies for Dietary Improvement

Poonam Bakheta*

Abstract

The dietary balance between omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) is crucial in modulating inflammation and promoting optimal physiological function. Modern diets, particularly in industrialized countries, are skewed heavily in favor of n-6 fatty acids, often reaching ratios as high as 1:20 or more, compared to the ideal range of 1:1 to 1:4. This imbalance is associated with the pathogenesis of numerous chronic diseases, including cardiovascular conditions, obesity, diabetes, neurodegenerative disorders, and certain cancers. This review integrates evidence from approximately 45 original research studies to discuss the biological relevance of the n-3/n-6 ratio, its implications for health, and feasible dietary strategies for restoring balance. It also explores historical and cultural dietary patterns, biochemical pathways, and emerging public health interventions. The restoration of a healthy n-3/n-6 ratio is not only a nutritional priority but a public health imperative.

Keywords: Omega-3 fatty acids (n-3 PUFAs), omega-6 fatty acids (n-6 PUFAs), n-3/n-6 ratio, polyunsaturated fatty acids, inflammation modulation

INTRODUCTION

Lipids are essential in human nutrition, serving as both a primary energy source and crucial components of cellular structures and signaling pathways. Among these, polyunsaturated fatty acids (PUFAs), particularly omega-3 (n-3) and omega-6 (n-6) fatty acids, play a critical role in maintaining physiological balance (Swanson et al., 2012) [1]. These fatty acids are termed “essential” because the human body cannot synthesize them due to the lack of desaturase enzymes required to introduce double bonds at specific positions in the fatty acid chain. Therefore, alpha-linolenic acid (ALA, n-3) and linoleic acid (LA, n-6) must be obtained from dietary sources. Historically, diets were balanced in these fatty acids, primarily from natural food sources like leafy greens, wild-caught fish, and grass-fed meat. However, with the rise of industrialized food systems and increased reliance on refined oils, this balance has been disrupted. As Simopoulos (2002) [2] noted, our ancestors likely consumed a balanced n-3 to n-6 ratio of approximately 1:1, whereas modern diets, particularly in Western and urban Indian settings, often present ratios as high as 15:1 or 20:1. This imbalance contributes to inflammation, altered lipid profiles, and an increased prevalence of chronic diseases.

Omega-3 fatty acids, especially EPA and DHA, have well-documented anti-inflammatory properties, helping to reduce the risk of cardiovascular diseases by improving lipid profiles and lowering blood pressure (Yashodhara et al., 2009) [3]. These beneficial effects extend to brain health and mental well-being, with sufficient omega-3 intake linked to a reduced risk of

*Author for Correspondence

Poonam Bakheta
E-mail: poonambakheta@pau.edu

Assistant Professor, Department of Food and Nutrition, College of Community Science, PAU, Ludhiana, Punjab, India

Received Date: May 10, 2025
Accepted Date: August 01, 2025
Published Date:

Correspondence: Poonam Bakheta. Striking the Right Balance: The Role of n-3/n-6 Fatty Acid Ratio in Health and Strategies for Dietary Improvement. International Journal of Nutritions. 2026; 3(1): 1–9p.

neurodegenerative diseases. Furthermore, omega-3s are vital for optimal immune function and may help prevent chronic inflammatory diseases. However, an imbalance in the intake of n-3 and n-6 fatty acids, with excessive n-6 and insufficient n-3, has been linked to the onset of chronic conditions, including cardiovascular diseases, due to the inflammatory effects of this imbalance (Othman et al., 2009) [4]. Restoring the right balance of these essential fatty acids through dietary adjustments is crucial for reducing disease risks and promoting overall health. This article explores the importance of achieving the proper n-3/n-6 fatty acid ratio and strategies for dietary improvement to enhance health and prevent disease.

IMPORTANCE OF N-3/N-6 FATTY ACID RATIO

The functional antagonism between n-3 and n-6 PUFAs is a key factor in the body's inflammatory responses. Both fatty acids are metabolized through shared enzyme pathways – specifically delta-6-desaturase and elongases – to produce long-chain metabolites, such as arachidonic acid (AA) from LA and EPA/DHA from ALA. Arachidonic acid-derived eicosanoids (prostaglandins, thromboxanes, and leukotrienes) generally promote inflammation, vasoconstriction, and platelet aggregation. In contrast, EPA, and DHA-derived eicosanoids exhibit anti-inflammatory and cardioprotective effects. Calder (2001) [5] highlighted that n-3 PUFAs, particularly EPA and DHA, can downregulate the production of pro-inflammatory cytokines and eicosanoids, thereby enhance immune regulation and reducing chronic inflammation.

An optimal ratio allows the body to balance these competing effects, promoting homeostasis and optimal immune functioning. An elevated n-6 intake without sufficient n-3 fatty acids shifts the body toward a pro-inflammatory state. This chronic low-grade inflammation underlies many non-communicable diseases (NCDs), including type 2 diabetes, atherosclerosis, rheumatoid arthritis, and even depression. Emerging research also suggests that the ratio impacts gene expression through peroxisome proliferator-activated receptors (PPARs), which regulate lipid metabolism and inflammatory processes (Calder, 2017) [6].

Moreover, researchers have highlighted that it is not merely the absolute intake but the ratio of n-3 to n-6 that determines health outcomes. For instance, increasing n-3 intake without reducing n-6 does not yield optimal benefits unless the ratio is improved simultaneously (Patterson et al., 2012) [7]. Hence, public health recommendations should aim at both increasing n-3 and moderating n-6 consumption.

HEALTH EFFECTS OF N-3/N-6 RATIO IMBALANCE

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. An imbalanced n-3/n-6 ratio exacerbates many cardiovascular risk factors, including high blood pressure, arterial stiffness, elevated triglycerides, and endothelial dysfunction. Numerous cohort and interventional studies, including those by Mozaffarian and Wu (2011), Kris-Etherton et al. (2002), and Rizos et al. (2012) [8, 9, 10], report that higher EPA and DHA intake significantly reduces cardiovascular events.

Omega-3 fatty acids reduce arrhythmias by stabilizing cardiac cell membranes and modulate heart rate variability (HRV). They also lower serum triglyceride levels, reduce platelet aggregation, and decrease the expression of pro-inflammatory genes, such as NF- κ B and TNF- α . Conversely, excessive n-6 fatty acid intake enhances the synthesis of prothrombotic and vasoconstrictive eicosanoids, thereby promoting plaque formation and arterial blockage. Connor (2000) [11] emphasized that n-3 fatty acids are crucial for cardiovascular health, neural development, and immune function, and their deficiency contributes to various chronic diseases. DiNicolantonio and O'Keefe (2018) [12] proposed that omega-6 vegetable oils, particularly through oxidized linoleic acid metabolites, may be a significant driver of coronary heart disease. They emphasized the need to reevaluate the widespread use of these oils given their potential pro-inflammatory and pro-atherogenic effects.

A study by Lemaitre et al. (2006) [13] showed a strong inverse association between plasma n-3 levels and the incidence of sudden cardiac death. As cardiovascular morbidity continues to rise, balancing the PUFA ratio offers a preventive, cost-effective strategy with widespread public health implications.

Adequate intake of omega-3 fatty acids is crucial for maintaining nutritional balance and promoting cardiovascular health. According to Gebauer et al. (2006) [14], consuming foods rich in omega-3s, such as fatty fish, flaxseed, and walnuts, is vital for achieving these health benefits and preventing cardiovascular disease. Alpha-linolenic acid (ALA), a plant-derived omega-3 fatty acid, contributes to cardiovascular health, even though its conversion to EPA and DHA is limited. A meta-analysis by Pan et al. (2012) [15] found that higher ALA intake was significantly linked to a reduced risk of cardiovascular disease, underscoring its role as a heart-healthy nutrient in plant-based diets.

Obesity and Metabolic Syndrome

The global obesity epidemic is closely intertwined with dietary changes, including increased consumption of seed oils and ultra-processed foods high in n-6 PUFAs. Simopoulos (2016) [16] postulated that excessive n-6 intake promotes adipogenesis via endocannabinoid pathways. These endogenous lipid messengers, derived from AA, stimulate fat storage and appetite.

Several animal studies and human trials have shown that higher dietary n-6 leads to more visceral fat accumulation, insulin resistance, and elevated inflammatory markers, such as C-reactive protein (CRP) (Lin et al., 2025) [17]. In contrast, n-3 fatty acids suppress lipogenesis, enhance fatty acid oxidation, and improve insulin sensitivity through PPAR- γ activation (Kalupahana et al., 2011) [18]. Clinical studies show that supplementation with EPA/DHA reduces waist circumference, fasting glucose, and markers of metabolic syndrome (Talon et al., 2015) [19].

A higher n-3/n-6 ratio also mitigates non-alcoholic fatty liver disease (NAFLD), an emerging metabolic concern. Therefore, modulating this ratio can be a significant lever in controlling the obesity pandemic, particularly in countries facing rapid nutritional transitions (Bogl et al., 2020) [20].

Cancer

Chronic inflammation is a known contributor to carcinogenesis. Excess n-6 fatty acid intake increases the synthesis of AA-derived prostaglandin E₂ (PGE₂), a pro-inflammatory mediator that promotes tumor growth, angiogenesis, and cell proliferation. Studies in colorectal, breast, and prostate cancers have consistently demonstrated that higher n-6 intake and a lower n-3/n-6 ratio correlate with greater cancer risk (Liu et al., 2021) [21].

EPA and DHA exert anti-carcinogenic effects by inducing apoptosis, suppressing COX-2 expression, and reducing oxidative stress. They also modify lipid raft composition in cell membranes, affecting signal transduction in cancer cells (Gogus and Smith, 2010) [22]. In breast cancer research, increased intake of EPA/DHA has been associated with reduced tumor size, improved chemotherapy tolerance, and better overall survival (Calder, 2006) [23].

Furthermore, animal models have shown that dietary n-3 fatty acids downregulate oncogenes and upregulate tumor suppressor genes. Hence, restoring balance in PUFA intake offers promising adjunctive benefits in cancer prevention and management (Gu et al., 2015) [24].

Mental Health and Neurodevelopment

The human brain is nearly 60% fat, with DHA being a key structural component of neuronal membranes, influencing neurotransmission, plasticity, and neuroprotection. Numerous epidemiological studies have linked low plasma DHA levels to an increased risk of mood disorders, ADHD, and neurodegenerative diseases like Alzheimer's (Zhou et al., 2024) [25]. Furthermore, omega-3 fatty acids, particularly DHA, have shown promise in supporting mental health. Freeman et al. (2006) [26] emphasized the potential of omega-3 fatty acids in the treatment of mood disorders, noting their critical role in reducing symptoms of depression and bipolar disorder, further highlighting the importance of DHA for both brain health and psychiatric well-being. Guesnet and Alessandri (2011) [27] also highlighted the critical role of DHA in the development of the central nervous system, especially during early life, underscoring the importance of ensuring adequate DHA levels for brain development and function.

Freeman et al. (2006) [26] found that countries with higher fish consumption had lower rates of depression and bipolar disorder. DHA and EPA reduce neuroinflammation, enhance dopaminergic signaling, and increase brain-derived neurotrophic factor (BDNF), essential for cognitive health. Randomized controlled trials have also shown that n-3 supplementation improves attention, learning, and social behavior in children with ADHD (Chang et al., 2024) [28].

Maternal nutrition plays a pivotal role in fetal brain development, with omega-3 fatty acids – particularly DHA – being essential during pregnancy and lactation. Helland et al. (2003) [29] demonstrated that maternal supplementation with very-long-chain n-3 fatty acids significantly improved children's IQ at age 4, underscoring the long-term cognitive benefits. Innis (2008) [30] reported that DHA accumulation in the fetal brain peaks during the third trimester, making adequate maternal intake critical for neurodevelopment. Oken et al. (2005) [31] and Ramakrishnan et al. (2012) [32] further supported these findings by showing that higher maternal fish consumption was associated with better infant cognition, even when accounting for mercury exposure. Insufficient maternal DHA levels have been linked to poor visual acuity and cognitive deficits in infants, reinforcing the importance of maintaining adequate DHA status throughout pregnancy.

Numerous studies suggest that omega-3 fatty acids, particularly DHA, may play a protective role against age-related cognitive decline and neurodegenerative conditions. Huang (2010) [33] critically reviewed existing literature and concluded that higher intake of omega-3s is associated with a reduced risk of Alzheimer's disease and slower cognitive decline, emphasizing their neuroprotective potential in aging populations.

Hence, improving the n-3/n-6 ratio is not only beneficial for managing neurodegenerative disorders but also crucial for the developmental health of future generations.

Inflammatory and Autoimmune Disorders

Autoimmune conditions, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease are marked by immune dysregulation and persistent inflammation. Excess n-6-derived mediators like leukotrienes and thromboxanes promote leukocyte infiltration, joint swelling, and tissue destruction (Patterson et al., 2012) [7].

Omega-3 fatty acids, particularly EPA and DHA, are converted into specialized pro-resolving mediators (SPMs), such as resolvins, protectins, and maresins, which actively resolve inflammation rather than just suppress it (Serhan and Levy, 2018) [34]. Clinical trials have shown that omega-3 supplementation reduces joint stiffness, pain scores, and the need for NSAIDs in patients with arthritis (Wall et al., 2010) [35].

In Crohn's disease and ulcerative colitis, n-3 fatty acids reduce cytokine storms and oxidative damage to the intestinal mucosa. The immunomodulatory effects of omega-3 PUFAs make them a promising non-pharmacological adjunct in the treatment of inflammatory and autoimmune diseases (Marton et al., 2019) [36].

GLOBAL TRENDS AND CAUSES OF IMBALANCE IN N-3/N-6 RATIO

Over the past century, globalization, industrial agriculture, and modern food processing have significantly altered dietary fat composition. Traditionally, humans consumed a nearly equal ratio of n-3 to n-6 fatty acids due to the availability of wild games, foraged plants, and marine foods. However, modern food systems have dramatically tipped this balance (Van Vliet and Katan, 1990) [37].

The primary contributors to this shift are vegetable oils rich in linoleic acid (such as soybean, sunflower, safflower, corn, and cottonseed oil), which have become staples in processed foods. As per the FAO data, global production and consumption of vegetable oils have increased manifold in the past few decades. In contrast, the intake of omega-3-rich foods like flaxseed, walnuts, chia seeds, fatty fish, and pasture-raised animal products has either remained stagnant or declined (Saidaiah et al., 2024) [38].

Several studies, including those by Simopoulos (2008) and Blasbalg et al. (2011) [39, 40], reveal that the average Western and urban Indian diets now have an n-6 to n-3 ratio ranging from 15:1 to 20:1, far beyond the evolutionary norm. Such trends are driven by:

- Increased availability and affordability of seed oils.
- Urbanization and processed food consumption.
- Reduced access to fresh, whole foods.
- Lack of public awareness regarding healthy fats.
- Absence of regulatory guidelines on ideal fatty acid ratios.

This dietary shift, although economically beneficial for the food industry, is a public health concern that demands urgent attention.

DIETARY STRATEGIES TO IMPROVE THE N-3/N-6 RATIO

Table 1. Summary of dietary sources and recommended intakes.

Nutrient	Rich food sources	Recommended intake	Key notes
ALA (n-3)	Flaxseeds, chia seeds, walnuts, soybeans, canola oil	1.1 g/day (women), 1.6 g/day (men)	Plant-based; limited conversion to EPA/DHA.
EPA & DHA (n-3)	Fatty fish (salmon, sardines, mackerel, trout), fish oil, algae	250–500 mg/day EPA+DHA	Crucial for heart and brain health.
LA (n-6)	Sunflower, safflower, corn, soybean oils, nuts, seeds	11–17 g/day	Keep within range; excessive intake can be harmful.
AA (n-6)	Eggs, poultry, meat	No specific RDA	Endogenously produced from LA
Ideal Ratio	–	1:1 to 4:1 (n-6:n-3)	Most current diets are 15:1 or higher.

Improving the dietary n-3 to n-6 fatty acid ratio requires both an increased intake of omega-3-rich foods and a reduction in excessive omega-6 consumption. While plant-based sources, such as flaxseeds, chia seeds, and walnuts are rich in ALA, the body's ability to convert ALA into the biologically active forms EPA and DHA is limited. As a result, many individuals fall short of the recommended levels of long-chain omega-3s. Meyer (2011) [41] emphasized that most populations do not consume adequate amounts of EPA and DHA for optimal health, highlighting the need for targeted dietary changes or supplementation.

Increase n-3 Fatty Acid Intake

- *Marine Sources:* Fatty fish, such as salmon, sardines, mackerel, herring, and anchovies are the richest sources of EPA and DHA. Regular consumption of 2–3 servings per week can significantly raise blood levels. Deckelbaum and Torrejon (2012) [42] highlighted that omega-3 fatty acids from marine sources are more bioavailable and exert stronger anti-inflammatory effects compared to plant-based ALA. They further noted that dietary interventions using marine omega-3s have shown consistent benefits in reducing the risk of chronic diseases.
- *Plant-Based Sources:* Plant-based sources, such as flaxseeds, chia seeds, walnuts, hemp seeds, and canola oil are rich in ALA (α -linolenic acid), which contributes to overall omega-3 status. Although the conversion of ALA to EPA and DHA is limited (~5–10%), it still plays a significant role in omega-3 metabolism. Goyens et al. (2006) [43] found that this conversion is influenced by the absolute amounts of ALA and linoleic acid in the diet, rather than the ratio between the two fatty acids, underscoring the complexity of dietary factors in omega-3 metabolism. Despite the conversion limitations, plant-based omega-3 sources remain an important dietary component for supporting health [44, 45].
- *Fortified Foods:* Omega-3-enriched eggs, dairy products, and functional beverages can improve intake in populations with limited seafood access.

- *Supplements*: Fish oil, krill oil, or algae-based omega-3 capsules are effective for individuals with dietary restrictions.

Reduce Excess n-6 Fatty Acid Intake

- Limit usage of refined vegetable oils (e.g., soybean, sunflower, corn oil).
- Replace with healthier alternatives like mustard oil, cold-pressed groundnut oil, or coconut oil.
- Avoid ultra-processed snacks, fried foods, and baked goods high in industrial fats.
- Read food labels for hidden sources of seed oils.

Promote Traditional and Local Diets

Traditional Indian diets based on millets, pulses, seasonal vegetables, mustard oil, and buttermilk naturally had a better n-3/n-6 ratio. Reviving these habits, along with community-level nutrition education, can drive long-term behavior change.

Public Health Policy Interventions

Governments and health authorities should:

- Issue dietary guidelines including recommendations for fatty acid ratios.
- Encourage agricultural policies favoring omega-3-rich crops.
- Fund awareness campaigns and community-based interventions.
- Encourage industry to reformulate products with improved fat quality.

By adopting these strategies, it is possible to restore a healthier balance of dietary fats and reduce the burden of chronic diseases. After detailing the benefits of omega-3 fatty acids across various health domains – including cardiovascular, cognitive, and developmental health – it is equally important to consider their safety profile. Lien (2009) [46] reviewed the toxicology and safety of DHA and concluded that it is well-tolerated, with no significant adverse effects observed even at high doses, supporting its safe use in clinical and dietary applications.

CONCLUSION

The dietary n-3/n-6 fatty acid ratio is a critical yet often overlooked aspect of nutritional health. Modern dietary patterns, marked by excessive n-6 intake and insufficient n-3 consumption, have shifted this balance in ways that promote inflammation, chronic disease, and metabolic dysfunction. A growing body of evidence from clinical trials, observational studies, and mechanistic research underscores the significance of restoring this ratio.

Improving the n-3/n-6 ratio is not merely about adding supplements – it requires a holistic shift in dietary practices, food production systems, and public health strategies. Whether it is reducing the reliance on refined seed oils, promoting omega-3-rich local foods, or enhancing consumer awareness, multi-level interventions are essential.

For countries like India undergoing rapid nutrition transitions, this presents a unique opportunity to realign public health goals with traditional wisdom. By focusing on this vital nutrient balance, it is possible to not only improve individual health outcomes but also reduce the societal burden of non-communicable diseases.

REFERENCES

1. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: Health benefits throughout life. *Adv Nutr.* 2012;3(1):1–7.
2. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. *Biomed Pharmacother.* 2002;56:365–379.
3. Yashodhara BM, Umakanth S, Pappachan JM, Bhat SK, Kamath R, Choo BH. Omega-3 fatty acids: A comprehensive review of their role in health and disease. *Postgrad Med J.* 2009;85(1000):84–90. doi: [10.1136/pgmj.2008.073338](https://doi.org/10.1136/pgmj.2008.073338). PMID: 19329703.

4. Othman RA, Suh M, Moghadasian MH. A systemic review of the roles of n-3 fatty acids in health and disease. 2009;668–679.
5. Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. *Lipids*. 2001;36(9):1007–1024.
6. Calder PC. Omega-3 fatty acids and inflammatory processes: From molecules to man. *Biochem Soc Trans*. 2017;45(5):1105–1115. doi: [10.1042/BST20160474](https://doi.org/10.1042/BST20160474). PMID: 28900017.
7. Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health implications of high dietary omega-6 polyunsaturated fatty acids. *J Nutr Metab*. 2012;2012:539426. doi: [10.1155/2012/539426](https://doi.org/10.1155/2012/539426). PMID: 22570770.
8. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation*. 2002;106(21):2747–2757.
9. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. *J Am Coll Cardiol*. 2011;58(20):2047–2067.
10. Rizos EC, Ntzani EE, Bika E. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. *Database of Abstracts of Reviews of Effects (DARE)*. 2012.
11. Connor WE. Importance of n-3 fatty acids in health and disease. *Am J Clin Nutr*. 2000;71(1 Suppl):171S–175S. doi: [10.1093/ajcn/71.1.171S](https://doi.org/10.1093/ajcn/71.1.171S). PMID: 10617967.
12. DiNicolantonio JJ, O'Keefe JH. Omega-6 vegetable oils as a driver of coronary heart disease: The oxidized linoleic acid hypothesis. *Open Heart*. 2018;5(2):e000898. doi: [10.1136/openhrt-2018-000898](https://doi.org/10.1136/openhrt-2018-000898). PMID: 30364556.
13. Lemaitre RN, King IB, Mozaffarian D, Sotoodehnia N, Rea TD, Kuller LH, et al. Plasma phospholipid trans fatty acids, fatal ischemic heart disease, and sudden cardiac death in older adults: The cardiovascular health study. *Circulation*. 2006;114(3):209–215. doi: [10.1161/CIRCULATIONAHA.106.620336](https://doi.org/10.1161/CIRCULATIONAHA.106.620336). PMID: 16818809.
14. Gebauer SK, Psota TL, Harris WS, Kris-Etherton PM. n-3 fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. *Am J Clin Nutr*. 2006;83(6 Suppl):1526S–1535S. doi: [10.1093/ajcn/83.6.1526S](https://doi.org/10.1093/ajcn/83.6.1526S). PMID: 16841863.
15. Pan A, Chen M, Chowdhury R, Wu JH, Sun Q, Campos H, et al. α -Linolenic acid and risk of cardiovascular disease: A systematic review and meta-analysis. *Am J Clin Nutr*. 2012;96:1262–1273. doi: [10.3945/ajcn.112.044040](https://doi.org/10.3945/ajcn.112.044040).
16. Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. *Nutrients*. 2016;8(3):128. doi: [10.3390/nu8030128](https://doi.org/10.3390/nu8030128). PMID: 26950145.
17. Lin S, Cienfuegos S, Ezpeleta M, Pavlou V, Corapi S, Runchey MC, et al. Time-restricted eating versus daily calorie restriction: Effects on inflammatory markers over 12 months in adults with obesity. *Nutrients*. 2025;17(7):1130. doi: [10.3390/nu17071130](https://doi.org/10.3390/nu17071130). PMID: 40218888.
18. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) fatty acids alleviate adipose tissue inflammation and insulin resistance: Mechanistic insights. *Adv Nutr*. 2011;2(4):304–316. doi: [10.3945/an.111.000505](https://doi.org/10.3945/an.111.000505). PMID: 22332072.
19. Talon LC, Erick PO, Moreto F, Portero-McLellan KC, Burini RC. Omega-3 fatty acids supplementation decreases metabolic syndrome prevalence after lifestyle modification program. *J Funct Foods*. 2015;19:922–928.
20. Bogl LH, Kaprio J, Pietiläinen KH. Dietary n-6 to n-3 fatty acid ratio is related to liver fat content independent of genetic effects: Evidence from the monozygotic co-twin control design. *Clin Nutr*. 2020;39(7):2311–2314. doi: [10.1016/j.clnu.2019.10.011](https://doi.org/10.1016/j.clnu.2019.10.011). PMID: 31668723.
21. Liu J, Li X, Hou J, Sun J, Guo N, Wang Z. Dietary intake of n-3 and n-6 polyunsaturated fatty acids and risk of cancer: Meta-analysis of data from 32 studies. *Nutr Cancer*. 2021;73(6):901–913. doi: [10.1080/01635581.2020.1779321](https://doi.org/10.1080/01635581.2020.1779321). PMID: 32530319.
22. Gogus U, Smith C. n-3 omega fatty acids: A review of current knowledge. *Int J Food Sci Technol*. 2010;45(3):417–436.
23. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *Am J Clin Nutr*. 2006;83(6 Suppl):1505S–1519S. doi: [10.1093/ajcn/83.6.1505S](https://doi.org/10.1093/ajcn/83.6.1505S). PMID: 16841861.

24. Gu Z, Shan K, Chen H, Chen YQ. n-3 polyunsaturated fatty acids and their role in cancer chemoprevention. *Curr Pharmacol Rep*. 2015;1(5):283–294. doi: [10.1007/s40495-015-0043-9](https://doi.org/10.1007/s40495-015-0043-9). PMID: 26457243.
25. Zhou K, Zhang Q, Yuan Z, Yan Y, Zhao Q, Wang J. Plasma fatty acids and attention deficit hyperactivity disorder: A Mendelian randomization investigation. *Front Psychiatry*. 2024;15:1368942. doi: [10.3389/fpsy.2024.1368942](https://doi.org/10.3389/fpsy.2024.1368942). PMID: 38764473.
26. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, et al. Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry. *J Clin Psychiatry*. 2006;67(12):1954–1967. doi: [10.4088/jcp.v67n1217](https://doi.org/10.4088/jcp.v67n1217). PMID: 17194275.
27. Guesnet P, Alessandri JM. Docosahexaenoic acid (DHA) and the developing central nervous system (CNS) – Implications for dietary recommendations. *Biochimie*. 2011;93(1):7–12. doi: [10.1016/j.biochi.2010.05.005](https://doi.org/10.1016/j.biochi.2010.05.005). PMID: 20478353.
28. Chang JP, Su KP, Mondelli V, Pariante CM. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: A systematic review and meta-analysis of clinical trials and biological studies. *Neuropsychopharmacology*. 2018;43(3):534–545. doi: [10.1038/npp.2017.160](https://doi.org/10.1038/npp.2017.160). PMID: 28741625.
29. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. *Pediatrics*. 2003;111(1):e39–44. doi: [10.1542/peds.111.1.e39](https://doi.org/10.1542/peds.111.1.e39). PMID: 12509593.
30. Innis SM. Dietary omega-3 fatty acids and the developing brain. *Brain Res*. 2008;1237:35–43. doi: [10.1016/j.brainres.2008.08.078](https://doi.org/10.1016/j.brainres.2008.08.078). PMID: 18789910.
31. Oken E, Wright RO, Kleinman KP, Bellinger D, Amarasiwardena CJ, Hu H, et al. Maternal fish consumption, hair mercury, and infant cognition in a U.S. cohort. *Environ Health Perspect*. 2005;113(10):1376–1380. doi: [10.1289/ehp.8041](https://doi.org/10.1289/ehp.8041). PMID: 16203250.
32. Ramakrishnan U, Grant F, Goldenberg T, Zongrone A, Martorell R. Effect of women's nutrition before and during early pregnancy on maternal and infant outcomes: A systematic review. *Paediatr Perinat Epidemiol*. 2012;26 Suppl 1:285–301. doi: [10.1111/j.1365-3016.2012.01281.x](https://doi.org/10.1111/j.1365-3016.2012.01281.x). PMID: 22742616.
33. Huang TL. Omega-3 fatty acids, cognitive decline, and Alzheimer's disease: A critical review and evaluation of the literature. *J Alzheimers Dis*. 2010;21(3):673–690.
34. Serhan CN, Levy BD. Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators. *J Clin Invest*. 2018;128(7):2657–2669.
35. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: The anti-inflammatory potential of long-chain omega-3 fatty acids. *Nutr Rev*. 2010;68(5):280–289. doi: [10.1111/j.1753-4887.2010.00287.x](https://doi.org/10.1111/j.1753-4887.2010.00287.x). PMID: 20500789.
36. Marton LT, Goulart RA, Carvalho ACA, Barbalho SM. Omega fatty acids and inflammatory bowel diseases: An overview. *Int J Mol Sci*. 2019;20(19):4851. doi: [10.3390/ijms20194851](https://doi.org/10.3390/ijms20194851). PMID: 31574900.
37. Van Vliet T, Katan MB. Lower ratio of n-3 to n-6 fatty acids in cultured than in wild fish. *Am J Clin Nutr*. 1990;51(1):1–2. doi: [10.1093/ajcn/51.1.1](https://doi.org/10.1093/ajcn/51.1.1). PMID: 2296923.
38. Saidaiah P, Banu Z, Khan AA, Geetha A, Somraj B. A comprehensive review of omega-3 fatty acids: Sources, industrial applications, and health benefits. *Ann Phytomed*. 2024;13(1):209–225.
39. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. *Am J Clin Nutr*. 2011;93(5):950–962. doi: [10.3945/ajcn.110.006643](https://doi.org/10.3945/ajcn.110.006643). PMID: 21367944.
40. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. *Exp Biol Med*. 2008;233(6):674–688.
41. Meyer BJ. Are we consuming enough long chain omega-3 polyunsaturated fatty acids for optimal health? 2011:275–280.
42. Deckelbaum RJ, Torrejon C. The omega-3 fatty acid nutritional landscape: Health benefits and sources. *J Nutr*. 2012;142(3):587S–591S. doi: [10.3945/jn.111.148080](https://doi.org/10.3945/jn.111.148080).
43. Goyens PL, Spiker ME, Zock PL, Katan MB, Mensink RP. Conversion of α -linolenic acid in humans is influenced by the absolute amounts of α -linolenic acid and linoleic acid in the diet and not by the ratio. *Am J Clin Nutr*. 2006;84:44–35.

44. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. *Am J Clin Nutr.* 2006;83(6 Suppl):1467S–1476S. doi: [10.1093/ajcn/83.6.1467S](https://doi.org/10.1093/ajcn/83.6.1467S). PMID: 16841856.
45. Brenna JT, Salem N Jr, Sinclair AJ, Cunnane SC. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. *Prostaglandins Leukot Essent Fatty Acids.* 2009;80(2-3):85–91. doi: [10.1016/j.plefa.2009.01.004](https://doi.org/10.1016/j.plefa.2009.01.004). PMID: 19269799.
46. Lien EL. Toxicology and safety of DHA. *Prostaglandins Leukot Essent Fatty Acids.* 2009;81:125–132. doi: [10.1016/j.plefa.2009.05.004](https://doi.org/10.1016/j.plefa.2009.05.004).

Galley Proof for Author's Review and Approval Only.

**Not for Distribution, Uploading, or Publication on Any Other Website (or Online Platform)
Except Journals Official Website.**